WO2025190325 - PHARMACEUTICAL COMBINATION OF KIF18A INHIBITOR AND TUBULIN INHIBITOR AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/190325
Publication Date
18.09.2025
International Application No.
PCT/CN2025/082195
International Filing Date
12.03.2025
Title **
[English]
PHARMACEUTICAL COMBINATION OF KIF18A INHIBITOR AND TUBULIN INHIBITOR AND USE THEREOF
[French]
COMBINAISON PHARMACEUTIQUE D'INHIBITEUR DE KIF18A ET D'INHIBITEUR DE TUBULINE ET SON UTILISATION
[Chinese]
KIF18A抑制剂和微管蛋白抑制剂的药物组合及用途
Applicants **
SIMCERE ZAIMING PHARMACEUTICAL CO., LTD.
Inventors
ZHOU, Feng
ZHOU, Lei
WANG, Ruina
XUE, Liting
QIN, Xiaokang
MENG, Xiaoqing
YU, Jian
LI, Zhengtao
TANG, Renhong
Priority Data
202410288354.4
13.03.2024
CN
202411016438.9
27.07.2024
CN
202411043089.X
31.07.2024
CN
202411138467.2
19.08.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2937 | |
| EPO | Filing, Examination, Granting | 24460 | |
| Japan | Filing, Examination, Granting | 2862 | |
| South Korea | Filing, Examination, Granting | 3542 | |
| USA | Filing, Examination, Granting | 7940 |
Total:
41,741
Contact Us
Abstract[English]
The present invention provides a pharmaceutical combination comprising a kinesin family member 18A (KIF18A) inhibitor and a tubulin inhibitor, a combination product or a pharmaceutical composition comprising the pharmaceutical combination, and use of the pharmaceutical combination, the combination product or the pharmaceutical composition for treating tumors. Formula (K).[French]
La présente invention concerne une combinaison pharmaceutique contenant un inhibiteur d'un membre 18A de la famille des kinésines (KIF18A) et un inhibiteur de tubuline, un produit de combinaison ou une composition pharmaceutique contenant la combinaison pharmaceutique, et l'utilisation de la combinaison pharmaceutique, du produit de combinaison ou de la composition pharmaceutique dans le traitement de tumeurs. Formule (K).[Chinese]
本发明提供了包含驱动蛋白家族成员18A(KIF18A)抑制剂和微管蛋白抑制剂的药物组合，包含所述药物组合的组合产品或药物组合物，以及所述药物组合、组合产品或药物组合物用于治疗肿瘤的用途。式（K）。